Why I invited investors into my lab: Adendra Therapeutics co-founder Caetano Reis e Sousa in conversation with The Francis Crick Institute

In December 2021, Apple Tree Partners (ATP), a leader in life sciences venture capital, announced the launch of Adendra Therapeutics Ltd, a spin-out of immunology research by Crick Principal Group Leader Caetano Reis e Sousa and his team. One year on, Caetano explains why working with ATP on early stage discovery research in his lab has been key to the early success of Adendra.

View full story

sGSN – DNGR-1 axis: a novel checkpoint in anticancer immunity?

Our founder Caetano Reis e Sousa has published a seminal paper with exciting translational implications: can we release the brakes on cross presentation of antigens released as a result of immunogenic cell death?

Download pdf